The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
about
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisAdverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacinOral anti-pseudomonal antibiotics for cystic fibrosisFluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosisSleep disturbance in children treated with ofloxacinClinical significance of microbial infection and adaptation in cystic fibrosis.Photosensitivity due to drugs.Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJAdvances in the pharmacotherapy of cystic fibrosis.Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light.Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.Drug-induced photosensitivity: culprit drugs, management and prevention.Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation.Quinolone antibiotic photodynamic production of 8-oxo-7, 8-dihydro-2'-deoxyguanosine in cultured liver epithelial cells.Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.Photosensitizing potential of ofloxacin.Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis.Ciprofloxacin-induced phototoxicity in an adult cystic fibrosis populationIdiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature
P2860
Q24188313-2102C2FF-EDD1-4064-8B02-3F2A0BF05515Q24202879-33FFFB7B-C04F-48A1-9FE2-9F3FBAA027BCQ24243916-BAF65F2B-1897-41D3-BBD8-D2B785508FE6Q24670225-46A0190C-2726-498C-AADE-92B662C5AF31Q26471106-7DB265A7-5616-4B88-8284-2F0E5AD8F1DCQ27004711-5C87DA51-C1DA-43EF-A3D9-6E4F5E1D056FQ28368305-445D1AC1-850D-496C-8B72-45DF16B65579Q34491552-B8B6E9EE-6320-416D-813B-807B244C4050Q34976057-0588F94C-3AD3-47A1-B794-563F220DCB2BQ35117101-EF5CCCC2-1CC9-449D-90C8-CD2309597CE1Q35596685-928A7A69-2F27-4644-9EA3-C28CCF4B56C3Q35897583-FDAE4046-4551-486F-9EAD-8DC6878AC2CCQ36754434-38CBC6D0-631E-4A52-8428-7AAE09B6550DQ37924276-ED5FFCE8-FF72-49D3-8233-036ED245FFB2Q39881191-6A81C695-3EAB-4CCB-AF21-C86403896ED6Q41107832-D0DCB348-C261-456C-B49B-8FD5BB04A300Q41782321-03CE0334-037F-4050-8F62-6C865B3788D5Q42612914-C38F9FA9-FA5D-4762-9BEE-42EA3F5D84F7Q54318026-F94D3D56-DEFA-4663-8D2E-A8FDC38A5102Q57913589-68F9F811-50D2-49BA-B619-F2803FB3D8CCQ58795536-4EBEC322-96D3-480A-BA4A-DBF2183A93A6
P2860
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
The efficacy and safety of cip ...... infection in cystic fibrosis.
@en
The efficacy and safety of cip ...... infection in cystic fibrosis.
@nl
type
label
The efficacy and safety of cip ...... infection in cystic fibrosis.
@en
The efficacy and safety of cip ...... infection in cystic fibrosis.
@nl
prefLabel
The efficacy and safety of cip ...... infection in cystic fibrosis.
@en
The efficacy and safety of cip ...... infection in cystic fibrosis.
@nl
P2093
P356
P1476
The efficacy and safety of cip ...... infection in cystic fibrosis.
@en
P2093
P304
P356
10.1093/JAC/20.4.585
P407
P577
1987-10-01T00:00:00Z